New triple therapy shows promise for tough lung cancer

NCT ID NCT06610734

Disease control Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a low dose of radiation to a combination of chemotherapy and an immunotherapy drug (adebrelimab) helps people with extensive-stage small cell lung cancer live longer. About 202 adults aged 18-75 who have not had prior treatment for this stage will take part. The goal is to see if this approach improves overall survival and delays cancer growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 202 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged 18 to 75 years, regardless of gender; * ECOG Performance Status (PS) score of 0-1; * Expected survival duration of no less than 8 weeks; * Histologically or cytologically confirmed extensive small cell lung cancer (according to the VALG staging system); * Subjects must not have received systemic therapy or radical radiotherapy for extensive SCLC prior to enrollment. Exclusion Criteria: * Tissue classifications of mixed small cell lung cancer and non-small cell lung cancer; * Patients who have undergone major surgical procedures within 28 days prior to the initial administration of the study drug, or those planning to undergo major surgery during the study period (as determined by the investigator); * Receipt of live attenuated vaccines within 28 days before the first dose or planned for the duration of the study; * Participation in another clinical trial within 28 days preceding initial dosing, involving any experimental agents; * History of receiving chest radiotherapy or plans for intensive chest radiotherapy prior to systemic therapy; * Any previous T-cell co-stimulation or immune checkpoint therapies administered; * Documented history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\&amp;#34;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small cell lung cancer extensive stage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small cell lung cancer extensive stage

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New triple therapy shows promise for tough lung cancer

What the study statuses mean